Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

New Primers Provide Significant Breakthrough in Assay Sensitivity

Published: Thursday, September 20, 2012
Last Updated: Thursday, September 20, 2012
Bookmark and Share
Swift Biosciences, Inc. has announced a new addition to its line of myT® Primer reagents for the detection of key cancer mutations.

myT BRAF-Ultra, an ultrasensitive version of myT BRAF, provides 0.01% sensitivity down to single copy detection of BRAF mutations and is now available from Swift.  myT BRAF-Ultra can detect less than 10 copies of mutant BRAF V600E/K with very low breakthrough amplification from a background of 10,000 Swift-myT-BRAF-Press-Releas.gifwild-type genomic DNA copies. While myT BRAF-Ultra works well with fresh frozen and FFPE samples, this level of sensitivity also makes the product ideal for use when the sample material is limiting or where the target is present at very low concentration, such as with circulating tumor cells (CTCs), serum, plasma and needle biopsies. Each myT BRAF-Ultra package includes sufficient reagents to assess up to 14 samples when run in triplicate, plus a positive and a negative control.

myT BRAF-Ultra is the newest addition to the myT Primer line of products.  The first product in the family, myT BRAF, can detect 1% mutant BRAF V600E/K present in a background of 1,000 wild-type genomic DNA copies with no breakthrough amplification from wild-type, resulting in assays that give definitive Yes/No answers over a wide dynamic range and reduce or completely eliminate the need for delta Ct methods to call results.  Each myT BRAF package includes sufficient reagents to assess up to 28 samples plus a positive and a negative control.

The extreme selectivity and reproducibility of myT Primers provides an increased level of confidence and convenience in qPCR assays and makes them ideal for use when the sample material is limiting or where the target is present at very low concentration.  Additional myT Primer reagents will be coming soon, including primers for high sensitivity detection of KRAS mutations in codons 12 and 13.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
The Genetic Roots of Adolescent Scoliosis
Scientists at the RIKEN Center for Integrative Medical Sciences in collaboration with Keio University in Japan have discovered a gene that is linked to susceptibility of Scoliosis.
A Gene-Sequence Swap Using CRISPR to Cure Haemophilia
For the first time chromosomal defects responsible for hemophilia have been corrected in patient-specific iPSCs using CRISPR-Cas9 nucleases
New Tool Uses 'Drug Spillover' to Match Cancer Patients with Treatments
Researchers have developed a new tool that improves the ability to match drugs to disease: the Kinase Addiction Ranker (KAR) predicts what genetics are truly driving the cancer in any population of cells and chooses the best "kinase inhibitor" to silence these dangerous genetic causes of disease.
Understanding the Molecular Origin of Epigenetic Markers
Researchers at IRB Barcelona discover the molecular mechanism that determines how epigenetic markers influence gene expression.
New Tech Enables Epigenomic Analysis with a Mere 100 Cells
A new technology that will dramatically enhance investigations of epigenomes, the machinery that turns on and off genes and a very prominent field of study in diseases such as stem cell differentiation, inflammation and cancer has been developed by researchers at Virginia Tech.
Access Denied: Leukemia Thwarted by Cutting Off Link to Environmental Support
A new study reveals a protein’s critical – and previously unknown -- role in the development and progression of acute myeloid leukemia (AML), a fast-growing and extremely difficult-to-treat blood cancer.
New Weapon in the Fight Against Blood Cancer
This strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Toxin from Salmonid Fish has Potential to Treat Cancer
Researchers from the University of Freiburg decode molecular mechanism of fish pathogen.
Study Finds Non-Genetic Cancer Mechanism
Cancer can be caused solely by protein imbalances within cells, a study of ovarian cancer has found.
Scientists Create CRISPR/Cas9 Knock-In Mutations in Human T Cells
In a project spearheaded by investigators at UC San Francisco, scientists have devised a new strategy to precisely modify human T cells using the genome-editing system known as CRISPR/Cas9.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!